« Back
Home /
Dacomitinib

Dacomitinib

Manufacturer	TargetMol
Category	Oncology Neuroscience Neural Signaling Reagents & Chemicals Molecules By Organ Bladder Cancer
Type	Molecules
Specific against	other
Amount	200mg
Item no.	TMO-T2483-200mg
Targets	EGFR
CASRN	1110813-31-4
eClass 6.1	32169090
eClass 9.0	32169090
Available
Short Description	Dacomitinib(PF299804; PF-00299804) is a highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
Shipping	cool pack
Storage	-20°
Target names or alias	PF-299804 , PF299 , PF-00299804
Molecular Weight	469, 94
Pathway	Angiogenesis\|\|\|JAK/STAT signaling\|\|\|Apoptosis\|\|\|Tyrosine Kinase/Adaptors
Target	Apoptosis\|\|\|EGFR

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 200mg

available

Delivery expected until 5/23/2024